AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19557400
Drug: Improved quality
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved quality of discharge summary with clinical pharmacists reviewing and providing feedback on the medication report before discharge.
Trial: 19557400
Drug: Patients using
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients using the ApoDos medication dispensing system.
Trial: 28862032
Drug: Heparin pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin pre-treatment
Trial: 28862032
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no heparin pre-treatment)
Trial: 28160513
Drug: Pru p
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pru p 3 sublingual immunotherapy (SLIT)
Trial: 11104556
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent carboplatin
Trial: 11372583
Drug: Intracutaneous indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracutaneous indomethacin (10 micrograms/ml and 100 micrograms/ml)
Trial: 11372583
Drug: Peroral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroral indomethacin (100 mg)
Trial: 11372583
Drug: Mepyramine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepyramine (10 micrograms/ml)
Trial: 11372583
Drug: Peroral zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroral zafirlukast (40 mg)
Trial: 9844453
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg/12 h) + Clarithromycin (500 mg/12 h) + Metronidazole (500 mg/12 h)
Trial: 9844453
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg/12 h) + Clarithromycin (500 mg/12 h) + Amoxicillin (1 g/12 h)
Trial: 7862925
Drug: m-chlorophenylpiperazine (mCPP)
RxNorm normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (mCPP) 0.4 mg/kg
Trial: 2510268
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg b.d.
Trial: 25925487
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality intervention protocol for pelvic floor muscle training (30 min, twice a week, total of 10 sessions)
Trial: 16681477
Drug: 20-mg tadalafil
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg tadalafil taken on demand
Trial: 2892392
Drug: Nizatidine 75
RxNorm normalized name: nizatidine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 75 mg
Trial: 9236562
Drug: Nizatidine 25
RxNorm normalized name: nizatidine 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 25 mg
Trial: 488880
Drug: 4.0 g
RxNorm normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 g Paromomycin administered on each of the two preoperative days combined with mechanical cleansing of the intestine
Trial: 23709409
Drug: Brain-directed nutrients
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain-directed nutrients (BDNs) including fish oil, a high-potency multiple vitamin/mineral supplement, and a brain-enhancement supplement.
Trial: 21216328
Drug: Methoxyflurane (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxyflurane (3 ml via hand-held inhaler)
Trial: 19638968
Drug: Warm water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm water consumption (2 l) before colonoscopy
Trial: 19638968
Drug: Cold water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold water consumption (2 l) before colonoscopy
Trial: 12885699
Drug: Sibutramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine treatment
Trial: 6315789
Drug: Topical antifungal
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungal cream (after clinical cure)
Trial: 21744011
Drug: Betaine plus
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine plus Creatine (BET+CR; 2+20 g/day)
Trial: 21744011
Drug: Betaine (BET;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine (BET; 2 g/day)
Trial: 19389877
Drug: Dapoxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine 60 mg
Trial: 11988597
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 to 300 mg/d)
Trial: 11988597
Drug: AF patients
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF patients on no antithrombotic therapy
Trial: 6102837
Drug: Cimetidine, 4
RxNorm normalized name: Cimetidine, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 4 x 400 mg
Trial: 30998824
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (600 mg)
Trial: 30998824
Drug: Intravenous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trastuzumab (loading dose 8 mg/kg; maintenance dose 6 mg/kg)
Trial: 25827291
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin 40mg/m2 (Arm C)
Trial: 25827291
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin 40mg/m2 and gemcitabine 125mg/m2 (Arm CG)
Trial: 9603534
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic prophylaxis
Trial: 15157383
Drug: Anticholinesterase drugs
RxNorm normalized name: acetylcholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinesterase drugs and steroids treatment
Trial: 6294732
Drug: Intramuscular placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular placebo
Trial: 28501100
Drug: Ibutilide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (1 mg intravenous)
Trial: 25676084
Drug: Enhanced external
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced external counterpulsation (EECP) therapy
Trial: 17877952
Drug: Neoadjuvant antihormonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant antihormonal therapy (tamoxifen and aromatase inhibitors)
Trial: 17877952
Drug: Tamoxifen as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen as primary treatment
Trial: 7665538
Drug: 25 mg/day
RxNorm normalized name: estradiol 0.025 MG/Day Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/day of clomipramine
Trial: 7665538
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day of clomipramine
Trial: 795375
Drug: Josamycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josamycin (2 g daily for 7 days)
Trial: 795375
Drug: Erythromycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (2 g daily for 7 days)
Trial: 29898836
Drug: Additional antiplatelet
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional antiplatelet therapy
Trial: 16229114
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (CC) 16 mg
Trial: 7890074
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ACE inhibitor)
Trial: 7890074
Drug: Captopril, 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 6.25 mg orally twice daily for 4 days
Trial: 2095164
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 81 mval/day MgSO4 for 3 days
Trial: 18214709
Drug: Low-dose IV
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IV cyclophosphamide (LD-CYC) 500 mg/dose for six fortnightly pulses (cumulative dose 3 g) followed by azathioprine (AZA)
Trial: 18214709
Drug: High-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IV cyclophosphamide (HD-CYC) maximum of 1 g/dose for six monthly pulses followed by two quarterly pulses, followed by azathioprine (AZA)
Trial: 18214709
Drug: High-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IV cyclophosphamide (HD-CYC)
Trial: 26777322
Drug: Prasugrel 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 30 mg
Trial: 16769598
Drug: Prasugrel 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 75 mg
Trial: 15446552
Drug: High-dose ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ifosfamide and etoposide combination or carboplatin combination
Trial: 15446552
Drug: High-dose ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ifosfamide and doxorubicin
Trial: 11376923
Drug: Methadone tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone tapering plus amantadine (200-300 mg per day)
Trial: 8357779
Drug: Cicletanine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine (200 mg)
Trial: 29332237
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of maltodextrin (placebo)
Trial: 27567966
Drug: Combined nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined nicotine replacement therapy/placebo and contingency management for attendance/abstinence
Trial: 20876621
Drug: Nebulized colistimethate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized colistimethate sodium (CMS) equivalent to 75 mg of colistin base in 4 mL of NSS
Trial: 11015164
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrochlorothiazide per day
Trial: 30109735
Drug: Interdisciplinary programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary programme based on healthy eating, physical exercise, and cognitive behavioural therapy
Trial: 24323034
Drug: combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined androgen blockade with luteinizing hormone‐releasing hormone agonist and bicalutamide (Control)
Trial: 22360332
Drug: 2% L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% L-carnitine applied topically for 3 weeks
Trial: 22360332
Drug: 0.5% or
RxNorm normalized name: PHENOL 0.5% ORAL SPRAY TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% or 1% L-carnitine in vitro
Trial: 18382819
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy group (n = 15)
Trial: 1815973
Drug: Dihydroergotamine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine 0.1 mg intravenously
Trial: 1815973
Drug: Dihydroergotamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine 0.5 mg intravenously
Trial: 1815973
Drug: Dihydroergotamine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (all doses)
Trial: 6292803
Drug: Doxycycline 300
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 300 mg orally
Trial: 6292803
Drug: Pivmecillinam 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 600 mg orally
Trial: 27502805
Drug: Foot reflexology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot reflexology treatment
Trial: 15259283
Drug: E2/NETA (estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/NETA (estradiol 2 mg plus norethisterone acetate 1 mg)
Trial: 7487618
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate (0.2%) given topically twice daily for 1 week
Trial: 28422874
Drug: Dexmedetomidine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine at 0.4 μg/kg/h
Trial: 25039244
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% potassium hydroxide (KOH) solution
Trial: 17445898
Drug: Preoperative sub‐Tenon's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative sub‐Tenon's capsule injection of 3 ml of 0.75% ropivacaine
Trial: 17445898
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sub‐Tenon's capsule injection of 3 ml of saline)
Trial: 16113430
Drug: Fluticasone (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (inhaled corticosteroid)
Trial: 12575211
Drug: First aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC)
Trial: 12575211
Drug: Second aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC and 1 x 10(6) units of aprotinin for intravenous bolus)
Trial: 12575211
Drug: Amrinone combined
RxNorm normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amrinone combined with aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC and amrinone bolus of 1 mg/kg followed by maintenance of 8 micrograms/kg.min)
Trial: 9613383
Drug: Isovolaemic haemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovolaemic haemodilution therapy (IHT) for 6 weeks with venesection and volume replacement using hydroxyethylstarch, targeting a haematocrit of 35%.
Trial: 7852229
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose intramuscular hepatitis B vaccine (2 micrograms at first, followed by 1 microgram each at 1, 2, and 6 months)
Trial: 7852229
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose intramuscular hepatitis B vaccine (10 micrograms each at 0, 1, and 6 months)
Trial: 25713462
Drug: Integrated neurocognitive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated neurocognitive therapy (INT)
Trial: 20683104
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg b.d.)
Trial: 17224034
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) administered in the wound
Trial: 10535234
Drug: Exposure-based contingency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based contingency management (CM) treatment
Trial: 7024200
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group with enhanced commitment (contracts signed by participant and at least one friend, relative, or peer)
Trial: 25528325
Drug: School-Located Vaccination
RxNorm normalized name: cetylpyridinium chloride Topical Spray [Rocco's Old School]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-Located Vaccination Clinics (SLVCs) for Tdap vaccine
Trial: 21883103
Drug: Structured exercise
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured exercise intervention (three weekly supervised sessions in a fitness center)
Trial: 15221991
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg) plus 5-fluorouracil/leucovorin (5-FU/LV)
Trial: 12149107
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of tap water
Trial: 1102383
Drug: Loesferron effervescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loesferron effervescent iron tablet
Trial: 30799502
Drug: IVO +
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IVO + IM discontinuation for patients with MRD‐CR
Trial: 27129119
Drug: GSK2485852 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2485852 70 mg
Trial: 22944150
Drug: Monthly e-newsletters
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monthly e-newsletters
Trial: 17456380
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg daily for two months
Trial: 7618457
Drug: Gonadotropin releasing
RxNorm normalized name: Gonadotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin releasing hormone agonist treatment (D‐Trp‐6‐LHRH depot) before hysterectomy
Trial: 26899745
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone 500 mg every 12 hours for 3 days
Trial: 26899745
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone 500 mg every 12 hours for 7 days
Trial: 16238908
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (EPO) 40,000 U once weekly
Trial: 12090862
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n = 1380)
Trial: 22313792
Drug: Desmopressin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin plus oxybutynin (5 mg)
Trial: 17767476
Drug: Rofecoxib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (25 mg/day) + Proton Pump Inhibitor (PPI)
Trial: 17767476
Drug: Proton Pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Pump Inhibitor (PPI) alone
Trial: 12680744
Drug: Procyclidine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procyclidine (15 mg, oral)
Trial: 10100062
Drug: Post-glucose load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-glucose load plasma insulin in hypertensive patients with microalbuminuria (n = 14)
Trial: 1802019
Drug: Mitoxantrone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 1.25 mg/m2/day
Trial: 31429205
Drug: TAK-385 (320/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 (320/80 mg loading/maintenance)
Trial: 31429205
Drug: TAK-385 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 (various doses)
Trial: 15612857
Drug: Alternative individual
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative individual treatment based on routine drug and alcohol therapy topics
Trial: 9394699
Drug: 90 g
RxNorm normalized name: Fora G90 Glucose Test Strip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g cooked field bean flour/d (groups B and C)
Trial: 9394699
Drug: 90 g
RxNorm normalized name: Fora G90 Glucose Test Strip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g raw field bean flour/d (group D)
Trial: 9394699
Drug: 90 g
RxNorm normalized name: Fora G90 Glucose Test Strip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g control flour/d (group A)
Trial: 7696825
Drug: Pamidronate (time-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (time-release preparation)
Trial: 7696825
Drug: Pamidronate (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (standard tablet preparation)
Trial: 7696825
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of pamidronate and use of antacid medication
Trial: 2954077
Drug: CAF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF (cyclophosphamide 600 mg/m2 + 5-fluorouracil 750 mg/m2 + adriamycin 45 mg/m2)
Trial: 28393781
Drug: Levosimendan at
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan at 0.1 μg/kg/min
Trial: 28393781
Drug: Dobutamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine at 5 μg/kg/min
Trial: 26237195
Drug: Conventional circular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional circular chainring (CC)
Trial: 10889125
Drug: Aggressive lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive lowering of LDL cholesterol levels to <100 mg/dL
Trial: 10889125
Drug: Low-dose anticoagulation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anticoagulation
Trial: 10889125
Drug: Moderate reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate reduction of LDL cholesterol to 132-136 mg/dL
Trial: 1568366
Drug: d-fenfluramine (d-F)
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (d-F) 15 mg, two capsules daily